COSMETIC INJECTABLES COMPLIANCE & CLINICAL GOVERNANCE

Map the entire patient journey rather than treating each obligation separately.

Assessment should lead clearly into prescribing, treatment, documentation and aftercare, while advertising should be reviewed separately against both health-practitioner requirements and the restrictions applying to prescription medicines.

The exact request will depend on the concern.

Relevant evidence may include the assessment, consultation, prescription, consent, medicine administered, treatment notes, aftercare and complication management, together with practitioner registration, training and clinic policies where the issue extends beyond one patient.

Not by itself.

Ahpra’s current non-surgical cosmetic procedure guidelines require an authorised practitioner to conduct an in-person or video consultation each time they prescribe a cosmetic injectable. Asynchronous prescribing by questionnaire, text or email is not considered acceptable practice.

A poor aesthetic result may involve dissatisfaction without clinical harm. A complication involves a clinical problem requiring assessment or management, while an adverse event may involve suspected harm associated with a medicine or device.

The distinction matters because the clinical response, documentation, escalation and potential reporting pathway may be different.

Not every unsatisfactory result needs to be reported as a therapeutic-goods adverse event.

Where a health professional suspects an adverse event involving a medicine or medical device, the TGA provides a specific adverse-event reporting pathway for health professionals. The clinic should still manage the patient’s immediate clinical needs regardless of whether a report is made.

Care is required because public advertising cannot directly or indirectly promote prescription-only medicines.

The TGA’s 2026 guidance also makes clear that terminology, price information and other contextual cues can amount to prescription-medicine advertising where they lead consumers to understand which medicine is being promoted.

Potentially, but it is not as simple as meeting Ahpra’s advertising requirements.

Ahpra has specific requirements around imagery used to advertise higher-risk cosmetic procedures. TGA restrictions also apply where advertising promotes, directly or indirectly, a prescription-only medicine.

The TGA has made clear that where it is apparent the “after” result was achieved using a prescription-only cosmetic injectable, the before-and-after image is likely to be considered prohibited advertising of that therapeutic good.

Not necessarily.

In our experience, clinics often assume competitor advertising is compliant because it is already in the market. We regularly see treatment terminology, promotions and messaging being used by other businesses that may not meet current requirements.

Your own advertising should be reviewed against the current Ahpra and TGA rules rather than using competitors as the benchmark.

Both practitioners are accountable for their part in the patient’s care.

The prescriber must assess the patient in a real-time consultation and remains responsible for the prescribing decision, including appropriate follow-up and aftercare.

The injector is responsible for safe administration and for raising any concerns with the prescriber.

Clinics should clearly document responsibility for assessment, prescribing, administration, aftercare and escalation so the patient is not left without support if a complication occurs.

They should understand the requirements relevant to their role.

Compliance training should not stop with injectors and prescribers. Staff speaking with prospective patients or publishing clinic content also need to understand what can be communicated about prescription cosmetic injectables.